Blunted growth hormone (GH) response to GH-releasing hormone in hypothyroidism resolves in the euthyroid state.
GH secretion is dependent upon thyroid hormone availability. In this study, the GH response to GH-releasing hormone (GHRH) was studied in a group of patients when they were hypothyroid and also when they were euthyroid. Hypothyroidism was associated with a significant reduction in both the peak GH response and the integrated GH secretory response to GHRH compared to those in the euthyroid state [4.7 +/- 1.6 (+/- SEM) vs. 12.2 +/- 3.9 ng/ml (P less than 0.025), and 349 +/- 116 ng vs. 986 +/- 304 ng ml-1 min-1 (P less than 0.025), respectively]. GH responsiveness was impaired within 2 weeks of discontinuation of T3 treatment in athyreotic subjects and was restored within 4 weeks of T4 treatment in one chronically hypothyroid subject. The results imply that a blunted GH response to GHRH in hypothyroidism is attributable to a primary pituitary defect that occurs rapidly and is reversible with attainment of the euthyroid state.
D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000188:drug therapy; D008875:Middle Aged; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000627:therapeutic use
D014284:Triiodothyronine; D013972:Thyrotropin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D013974:Thyroxine